Injectable Drug Delivery Market worth $624.5 Billion by 2021

This report defines the injectable drug delivery market size based on type, formulation packaging, therapeutic application, usage pattern, site of administration, distribution channel, facility of use, and region.

(EMAILWIRE.COM, August 19, 2021 ) Driver for Injectable Drug Delivery Market: Growth in biologics market

According to the American Journal of Managed Health Care, biologics form the fastest-growing segment in the pharmaceutical market. An article published by PHARMAC stated that between 2007 and 2012, the global spending on all medicines increased by 24%; in the same period, the spending on biologics increased by 367%.

According to an article published by The Economist, in the U.S., more than 900 biologics are under development for the treatment of more than 100 diseases. It is estimated that approximately USD 170 billion is spent on biologics globally, and this figure is expected to grow to approximately USD 220 billion by 2017.

A major factor responsible for this trend is the rising demand for vaccines, insulin, human growth hormone, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150

By type, the formulation segment to witness the highest growth during the forecast period (2016–2021).

Based on type, the injectable drug delivery market is further segmented into formulation, and devices. The formulation segment is expected to grow at the highest CAGR during the forecast period. The high growth of this market segment is attributed to the growing prevalence of chronic diseases, patient adherence, and the rising adoption of self-injection, new technologies, and biologics.

By facility of use, the hospitals and clinics segment to dominate during the forecast period

The hospitals and clinics segment are expected to dominate the market. The large share of this segment is attributed to the rising prevalence of chronic diseases, patient compliance, and technological advancements.

North America to account for the largest market size during the forecast period.

North America is expected to hold the largest market size in autoinjector market during the forecast period, followed by the European region. Factors such as the increasing incidence of chronic diseases, growth of biologicd market, and increasing demand of self-injection devices.

Asia is the third-largest market for Needle-free injector market. This market is poised to witness the highest growth due to the increasing prevalence of chronic diseases, rise in disposable income, growing awareness on safety and comfort, and increasing number of partnerships in this market space.

Revenue Growth Expectations:

MarketsandMarkets forecasts the injectable drug delivery market to grow from USD 362.4 billion in 2016 to USD 624.5 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 11.5% during the forecast period.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=150

Prominent players in the injectable drug delivery market include Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com